MENU
MED TECH

Medtec Grand Prix KOBE2023

Standing up for solutions to society's problems
Drug discovery, medical devices, regenerative medicine, healthcare, research tools, etc.
We implement the technologies and thoughts of entrepreneurs and researchers in the MedTech area into society together.
NEWS
MedTech Grand Prix KOBE2023: Grand Prize Won by PNP Vision
2023/10/13 MedTech Grand Prix KOBE2023: Grand Prize Won by PNP Vision
  • Grand Prix
  • News
  • Medtec Grand Prix KOBE
MedTech Grand Prix KOBE2023 Finalists have been selected!
2023/09/07 MedTech Grand Prix KOBE2023 Finalists have been selected!
  • News
  • Medtec Grand Prix KOBE
6/8, Online】 Entry Information Session for MEDTEC GRAND PRIX KOBE2023 will be held.
2023/05/16 6/8, Online】 Entry Information Session for MEDTEC GRAND PRIX KOBE2023 will be held.
  • News
  • Medtec Grand Prix KOBE
MEDTECH Seminar 2023 will be held on Thursday, May 18, 2012.
2023/04/24 MEDTECH Seminar 2023 will be held on Thursday, May 18, 2012.
  • Medtec Grand Prix KOBE
ABOUT
point (e.g. of a statement)
Scientific and technological "seeds" are being created in universities, research institutes, and corporate laboratories, but it takes a lot of effort before they sprout into practical applications. The "Tech Planter," organized by RIVANES and its partners, is an ecosystem that aims to serve as a planter to discover these seeds and help them sprout into businesses. The "MedTech Grand Prix KOBE" is a program aimed at discovering and fostering technology seeds and entrepreneurs in the real tech field (drug discovery, medical devices, regenerative medicine, healthcare, research tools, etc.).
subject (of taxation, etc.)
  • Those who have a vision to change the world or improve the world based on the technological seeds in the real tech field and have a will to establish or develop a new business.
  • Individuals and teams are both welcome to participate, even before incorporation.
  • No limitation on the number of years of establishment, even if you are already a corporation. Even if you are close to mass production or PMF establishment, if you are planning to collaborate with partner companies, etc., it is acceptable.
Application Theme
New prevention, diagnosis and treatment
Application period
Wednesday, March 1, 2023 - Friday, July 7, 2023
Screening Criteria
A panel of judges composed of LIVERNESS and its partners will review the following items
  1. 01novelty (patentability)
  2. 02feasibility
  3. 03Overseas Expansion Capabilities
  4. 04Are you going to change the world?
  5. 05passion
commendation
Grand Prize: (300,000 yen cash prize + right to receive 5 million yen business investment) 1
Corporate Prize: (200,000 yen) Approximately 10 prizes will be awarded.
SCHEDULE
3/1[WED]

Entry Start

this way (direction close to the speaker or towards the speaker)Please register as a member and fill out the web form to apply.
We also hold information sessions on a college-by-college and individual basis to encourage determination to enter and to teach tips on document preparation. Please feel free to contact us for more information.

6/17[SAT]

kickoff

RIVANES and its partners, as well as entered teams, will meet and mingle.
Business consultation and partnership development with each other will be available. Participation or lack of participation on the day of the event will not be considered.

7/10[MON]

1st round: Application Screening

A panel of judges composed of LIVERNESS and its partners will review the documents.
You will be asked to submit information about your team, skills, passions, and vision for the future via web form and video.
All applicants will be notified of the screening results and provided with feedback on their applications.
In addition, individual interviews (also online) for presentation review will be conducted for those who wish to participate.

8monthfirst 10 days of month

Finalists determined

Interviews will be held for applicants who pass the document screening to brush up their presentations for the final round.
In addition, meetings can be set up with partner companies for the purpose of business consultation and developing partnerships.

10/7[SAT]

Medtec Grand Prix KOBE

The 12 finalist teams that pass the document screening will be screened for presentation.

10Month～

Matching Support Period

After the Demo Day, the contact point between the venture and LIBANES will continue to be open for discussions on commercialization.
We handle a wide range of start-up issues, from incorporation to prototype development, financing, R&D, and more.
In addition, collaborative matching between ventures and partner companies has become more active to support business development.

PARTNER
  • Eisai Co.
  • Chiome Bioscience Inc.
  • Kirin Holdings Company, Limited
  • Sysmex Corporation
  • Taisho Pharmaceutical Co.
  • Dai Nippon Printing Co.
  • Meiji Holdings Co.
  • Euglena Co.
  • Rohto Pharmaceutical Co.
ASSET
  1. ASSET01Riverness Communicator
  2. ASSET02Partners
  3. ASSET03Professional Supporter
  4. ASSET04superfactory group
SUPPORT
  1. SUPPORT01Organize the purpose and vision of starting a business
  2. SUPPORT02Brush up on your presentation
  3. SUPPORT03Providing opportunities for business company collaboration
  4. SUPPORT04Support for R&D and prototype development
  5. SUPPORT05Support for knowledge and IP strategies
  6. SUPPORT06finance
DEMO DAY
Grand Prix Name
Medtec Grand Prix KOBE2023
Location
Kobe University Integrated Research Center Convention Hall
Date & Time
Saturday, October 7, 2023, 13:00-19:10
Application period
Wednesday, March 1, 2023 - Friday, July 7, 2023
Participation Target
Held on a closed, pre-registration basis (finalists, partner companies, professional supporters, Super Factory Group)
organizing
City of Kobe, Kobe Medical Industry Development Organization, RIVANES Co.
timeline
12:30-13:00
inauguration
13:00-13:30
Greetings from the Organizer
13:30-17:00
Presentation (Presenter①～⑫)
17:00-18:00
Review Time
18:00-19:10
Announcement of Judging Results and Award Ceremony
JUDGE
  • Chenio Hanai
    head judge
    Director, Liberace Capital Co.
    Chenio Hanai
    In 2003, he established BioWa, Inc. in the U.S. to out-license the antibody-related technologies he had developed, and was appointed president and responsible for the company's operations. He was appointed Chairman of the Board in 2018 and Chairman of the Board in 2019, He retired in March 2020 and became a director of Liverness Capital in May of the same year.
  • Masakatsu Imoto
    Director, Cluster Promotion Center, Kobe Medical Industry Development Organization
    Masakatsu Imoto
    After joining the Ministry of Health, Labour and Welfare (now the Ministry of Health, Labour and Welfare), he was responsible for the revision of various drug standards, review and safety measures for medical devices, review of pharmaceuticals, the NHI drug price system, revision of medical guidelines and enactment of the Clinical Research Act, and promotion of research and development focusing on clinical development systems for drugs and medical devices. He has served as Executive Officer of PMDA (in charge of Next Generation Evaluation Methodology Promotion and Medical Information Utilization) before assuming his current position.
  • Takashi Yamamoto
    Vice Chancellor, The University of Tokyo
    President, The University of Tokyo Extension Co.
    Kobe Medical Industry Development Project Start-up Supporter
    Takashi Yamamoto
    Graduated from Chuo University. After leaving Recruit Co., Ltd. in 2000, he became President and Representative Director of the Incubation Center for Advanced Science and Technology (now the University of Tokyo TLO, Inc.). In 2023, he retired as President and Representative Director of the University of Tokyo TLO and was appointed as Advisor. Also serves as Deputy Director of RIKEN and Director of RIKEN Dingyo Co.
  • Teiji Kimura
    Senior Executive Officer, Academia & Industry Officer, DHBL Office, Eisai Co.
    Teiji Kimura
    He joined Eisai Inc. in 1987 and was involved in several CNS drug discovery projects as a chemist. Since 2010, he has overseen drug discovery activities at four global CNS research sites, contributing to the creation of disease-modifying drugs for Alzheimer's disease and insomnia, etc. He will assume his current position in 2022. He has been working on partnerships with diagnostics companies to realize precision medicine and external knowledge initiatives aimed at enhancing the drug discovery pipeline, including digital therapies.
  • Uzuhiko Bijyohira
    Director and General Manager of Corporate Planning Office, Chiome Bioscience Inc.
    Uzuhiko Bijyohira
    While in college, he joined the Industrial Development Institute of Japan, Inc. and was mainly engaged in management consulting activities for the manufacturing industry. He joined Chiome Bioscience in 2013. After serving as General Manager of Corporate Planning Department and Executive Officer and General Manager of Corporate Division, he assumed his current position in 2017.
  • Shigehito Ikushima
    Senior Manager, Health Science Division, Kirin Holdings Company, Limited
    Shigehito Ikushima
    2004 Joined Kirin Brewery Company (now Kirin Holdings Company, Limited). D. in Agriculture. D. in Agricultural Science, working on solving social issues based on fermentation and biotechnology. In the age of 100 years of life, he is particularly interested in technologies related to immunity, the intestinal environment, and substance production in order to contribute to people's health.
  • Tomokazu Yoshida
    Director, Managing Executive Officer, CTO, Sysmex Corporation
    Tomokazu Yoshida
    After graduating from Okayama University Graduate School with a doctorate in pharmaceutical sciences in 1995, he was engaged in cardiovascular research and drug discovery research in the fields of central nervous system diseases and oncology at national research institutes and pharmaceutical companies. In 2021, he was appointed as Director, Managing Executive Officer, and in 2023, he assumed his current position.
  • Shinichi Nishimoto
    Director, Frontier Research Center, Taisho Pharmaceutical Co.
    Shinichi Nishimoto
    Dr. Kato joined Taisho Pharmaceutical in 1997. In 2019, he moved to the newly established Frontier Research Center, where he started startup investments and collaborations aimed at creating new businesses in the healthcare and drug discovery fields. He has been Deputy Director of the Center since April 2022, and assumed his current position in October 2023.
  • Hiroto Iris
    Dai Nippon Printing Co.
    Deputy General Manager, First Development Department, Food and Healthcare Business Development Unit, Business Development Division, Research, Development & Commercialization Center
    Hiroto Iris
    Graduated from Tokyo University of Science, Faculty of Science in 2002, engaged in research on biomaterials at Tokyo Medical and Dental University, and obtained a Ph. Since joining DNP in 2008, he has been engaged in the development of regenerative medicine-related technologies. After working on joint development with Tokyo Medical and Dental University and Osaka University, he has been in his current position since 2022, promoting commercialization of regenerative medicine-related technologies. He is also a member of the Regenerative Medicine Innovation Forum, Vice-Chairman of the Supporting Industry Committee, and a member of the Society for Regenerative Medicine, Public Relations Committee, and other external committees.
  • Yuta Watanabe
    General Manager, Development Project Management Department, Research & Development Division, Meiji Seika Pharma Co.
    Yuta Watanabe
    He has been involved in global pharmaceutical R&D for nearly 30+ years, leading the development of a variety of cutting-edge medical products. He also served as the head of the New Business Division, leading the creation of new healthcare solutions including digital from deep tech and VC activities. In his current position, he will oversee the development of new pharmaceuticals from 2022.
  • Ayaka Nakajima
    Director, Human Science Research Institute, Euglena Co.
    Ayaka Nakajima
    At Euglena Co., Ltd. he established a department to research the functionality of euglena when consumed as food and when used in cosmetics. At the same time, he also oversees the development of new materials based on euglena, and continues to explore the value and potential of euglena, which was previously unknown as a material. In addition to his research, he holds a master's degree in business planning and is involved in a wide range of activities to link the results of his research to health behavior change and business. D. in Food and Nutrition.
  • Tsuyoshi Ishii
    General Manager, Laboratory Medicine and Instrument Development Department, Rohto Pharmaceutical Co.
    Tsuyoshi Ishii
    After graduating from the Faculty of Pharmaceutical Sciences at Osaka University and completing the master's program at the same university, he joined Rohto Pharmaceutical in 1997 and was assigned to the Research and Development Division, where he was mainly engaged in basic research on skin aging and the development of functional cosmetics. In 2013, he joined the company's Regenerative Medicine Research and Planning Department, where he was involved in the development of regenerative medicine products. From 2023, he will be engaged in the research and development of diagnostic reagents and medical devices at his current position.
FINALIST
  •  
    Tomohiro Oiwa
    Arktus Therapeutics, Inc.
    Representative】Tomohiro Oiwa
    Research and development of cellular knee prostheses derived from iPS cells

    Research and development of cellular knee prostheses derived from iPS cells

    The company will develop an artificial knee joint derived from iPS cells to realize a new medical treatment for knee joint diseases. Existing metal knee prostheses are not suitable for patients under the age of 60 or those who wish to continue active exercise, and will provide a new treatment option for such patients with severe disease.
  • Taisho FRC Award
    Kenji Izumi
    CollaWind Inc.
    Representative] Kenji Izumi
    Providing collagen sheets for early healing of gum wounds

    Providing collagen sheets for early healing of gum wounds

    We have developed a fish-derived collagen sheet with a wavy structure that mimics human gum tissue. We will establish a business to supply this new material to (1) the research and development field (for university laboratories, companies, and animals), (2) the beauty field, and (3) the medical field, where there is a need for this new material.
  • Sysmex Award
    Taiga Nishimura
    MEDEMIL Corporation
    Representative] Taiga Nishimura
    Diagnosis of the brain through the eyes for prevention of automobile accidents and early detection of diseases

    Diagnosis of the brain through the eyes for prevention of automobile accidents and early detection of diseases

    It is well known that the eyes can reflect the state of the brain and body. We have established a technology to estimate driving ability and disease information by AI analysis of eye movement data of subjects. Our goal is to prevent automobile accidents among the elderly, which is a social problem, and to detect diseases at an early stage.
  •  
    Yasuyuki Yokozaki
    Institute for Antibody Medicine, Inc.
    Representative] Yasuyuki Yokozaki
    Descending into the Valley of Death with Antibodies Raised -The Challenge of Pulmonary Fibrosis

    Descending into the Valley of Death with Antibodies Raised -The Challenge of Pulmonary Fibrosis

    Twenty years after the idea was conceived in a university laboratory, an integrin-neutralizing antibody was produced and its pharmacological effects on fibrosis were confirmed. We are now working to develop a drug to stop/restore fibrosis, which is not yet available, to patients. We would like to show that academia drug discovery crosses the valley of death.
  •  
    Makoto Inoue
    Inpharmacia Corporation
    Representative] Makoto Inoue
    Working Fat" for a Healthier Society Even in Old Age

    Working Fat" for a Healthier Society Even in Old Age

    The ultra-safe gene therapy technology that can transform subcutaneous fat into "working fat" - body tissue that can treat and prevent aging-related diseases - through subcutaneous injections will create a world without disease, even in old age. A world without disease, even in old age.
  • Eisai Award
    Toru Nakanishi
    Regenerforty Corporation
    Representative] Toru Nakanishi
    Treatment of Spinal Cord Injury with Novel Neural Stem Cell Culture Supernatant

    Treatment of Spinal Cord Injury with Novel Neural Stem Cell Culture Supernatant

    Using NEcST culture supernatant, a neural stem cell produced by our unique regenerative medicine technology, we will treat patients with spinal cord injury to restore their motor skills and return them to society. The company will also apply this cell culture supernatant to the treatment of pet animals that have lost the ability to walk due to spinal cord injury or spinal cord infarction.
  •  
    Yasuo Sumida
    Sudix Biotech, Inc.
    Representative] Yasuo Sumida
    Development of a new treatment for cancer using anti-carbohydrate antibodies

    Development of a new treatment for cancer using anti-carbohydrate antibodies

    Antibodies against highly specific sugar chains on the surface of cancer cells that serve as tumor markers are difficult to produce, but we have established a method for producing anti-sugar chain single chain antibodies for liver and blood cancer cells using sugar chain nanotechnology and are developing photodynamic therapy and cellular immunotherapy for cancer that incorporate these antibodies.
  • Real Tech Fund Award
    Tetsuya Nakamae
    killer T
    Representative] Tetsuya Nakamen
    Development of Cancer mRNA Vaccine for Cancer Eradication

    Development of Cancer mRNA Vaccine for Cancer Eradication

    We have identified five membrane protein common cancer antigens that cover all cancers. We will develop a cancer mRNA vaccine that is applicable to all cancer patients by mixing them to prevent recurrence of cancer patients after surgery and realize an era in which all cancer patients can live longer.
  • Grand Prize / DNP Award
    Kanade Ryuzaki
    PNP Vision
    Representative] Kanade Ryuzaki
    Cancer diagnostic device using single-particle analysis technology

    Cancer diagnostic device using single-particle analysis technology

    Using its proprietary "single-particle surface molecular analysis technology," the company is building a cancer detection technology that is independent of cancer type based on the surface molecular information of biological particles contained in blood, with the ultimate goal of creating a world in which "anyone can easily test for cancer throughout the body" during physical examinations.
  •  
    Ruyoshi Takeuchi
    alkanchelle
    Representative] Ruyoshi Takeuchi
    Development of a rehabilitation support system to induce brain function activation

    Development of a rehabilitation support system to induce brain function activation

    For patients with upper arm and hand paralysis caused by cerebrovascular disease, we devised a method of incorporating the patient's cerebrum as part of a rehabilitation system in a non-invasive manner and developed an actual prototype system (Narem) that enables more efficient rehabilitation support.
  • Meiji Holdings Award / Kobe Medical Industry Development Project Award
    Satoshi Egawa
    OsteoChemicals
    Representative] Satoshi Egawa
    Creation of a novel osteogenic drug with strong osteoinductive potential

    Creation of a novel osteogenic drug with strong osteoinductive potential

    Bone formation is important in the treatment of orthopedic diseases, and we have succeeded in synthesizing a compound with vigorous bone induction based on a completely new idea. We are aiming for clinical application of this compound, which is a dream come true for orthopedic surgeons.
  • Chiome Bioscience Award
    Keiichi Nakayama
    Anti-Cancer Technologies, Inc.
    Representative] Keiichi Nakayama
    Development of photoimmunotherapy-based eradication of pancreatic cancer stem cells

    Development of photoimmunotherapy-based eradication of pancreatic cancer stem cells

    We have identified Molecule X specifically expressed in pancreatic cancer stem cells and found that ablation of cells expressing Molecule X in a mouse model completely eliminates pancreatic cancer. In order to apply this technique to humans, we will perform photoimmunotherapy using an antibody against Molecule X.
LIGHTNING TALK
Team Name theme representative
F.MED Corporation Development of a microsurgery support robot Keita Shimomura
Digital Spirits technology Wearable Technology for Social Change in Eye Health Care Kyosuke Futami
Bio Gel Growth Angiogenesis-promoting technology that does not require co-transplantation of vascular endothelial cells Toru Ohtani
visualizeGene All-in-One Genetic Testing System Takayuki Shibata
PITTAN Corporation Sweat Analysis for Inner Care Makoto Tsunoda
MED TECH10/7holding a meeting
Applications are closed
I did